Genomind, LLC specializes in neuropsychiatric personalized medicine and was formed to facilitate the adoption of personalized medicine into psychiatry by providing biomarker information to better understand the patient. The company was founded by Ronald I. Dozoretz, MD, in 2009, and is advised by a group of renowned experts in the fields of human genetics, psychopharmacology, and neuropsychiatric medicine.
Genomind is committed to the development and commercialization of an integrated approach and product, the Genecept™ Assay, which combines proprietary biomarker tests and an analytical report to be used by clinicians. In addition, the Genecept Assay is coupled with Genomind psychopharmacologist assistance for clinicians, together with emerging education and information concerning psychiatric disorders and pharmacogenomics. Genomind has unique intellectual property for this integrated approach and product.
Genomind's biomarker tests are not to be used for diagnosis, but rather as a tool for clinicians to more fully understand their patient’s genotype and assist in understanding potential response to medications.
More information is available at our website.